Adherence and persistence to second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

被引：0
|
作者：
Trivedi, Digisha
Amin, Shahla
Zhu, Ling
Joo, Sam
Kawabata, Hugh
Darkow, Theodore
Hebden, Tony
机构：
[1] Bristol Myers Squibb, Hlth Serv, Plainsboro, NJ USA
[2] Bristol Myers Squibb Co, Global Hlth Econ & Outcomes Res, Pennington, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17009
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
    Swords R.
    Alvarado Y.
    Cortes J.
    Giles F.J.
    Current Hematologic Malignancy Reports, 2007, 2 (2) : 83 - 88
  • [2] Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors
    Maeda, Yasuhiro
    Okamoto, Atsushi
    Kawaguchi, Shin-ichiro
    Konishi, Akiko
    Yamamoto, Kenta
    Eguchi, Go
    Kanai, Yoshitaka
    Yamaguchi, Terufumi
    ACTA HAEMATOLOGICA, 2017, 138 (03) : 140 - 142
  • [3] Chronic Myeloid Leukemia Therapy: Focus on Second-Generation Tyrosine Kinase Inhibitors
    McFarland, K. Leigh
    Wetzstein, Gene A.
    CANCER CONTROL, 2009, 16 (02) : 132 - 140
  • [4] Impact of Second-Generation Tyrosine Kinase Inhibitors As Second Line Treatment for Patients with Chronic Myeloid Leukemia
    Valentin Garcia-Gutierrez, J.
    Herrera, Pilar
    Abalo, Lorena L.
    Dolores Rey, Maria
    Calbacho, Maria
    Ramos, Lourdes
    Ramos, Paloma
    Montalban, Carlos
    Lopez-Jimenez, Javier
    BLOOD, 2011, 118 (21) : 1615 - 1615
  • [5] Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia with Additional Chromosomal Abnormalities
    Takahashi, Naoto
    Yoshioka, Tomoko
    Kizaki, Masahiro
    Kawaguchi, Tatsuya
    Suzuki, Ritsuro
    Yamamoto, Kazuhito
    Ohnishi, Kazunori
    Naoe, Tomoki
    Matsumura, Itaru
    BLOOD, 2019, 134
  • [6] Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
    Garcia-Gutierrez, Valentin
    Hernandez-Boluda, Juan Carlos
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 14
  • [7] Impact of Prior Second-Generation Tyrosine Kinase Inhibitors on the Outcome of Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia.
    Benedicte, Deau
    Emmanuel, Bachy
    Nicole, Raus
    Franck-emmanuel, Nicolini
    Delphine, Rea
    Oumedaly, Reman
    Natacha, Maillard
    Ame, Shanti
    Nathalie, Fegueux
    Valerie, Coiteux
    Martine, Gardembas
    Aude, Charbonnier
    Anne, Huyn
    Yves, Cahn Jean
    Agnes, Buzyn
    BLOOD, 2010, 116 (21) : 933 - 933
  • [8] Second-Generation Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Tefferi, Ayalew
    CANCER, 2011, 117 (02) : 234 - 237
  • [9] Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?
    Jabbour, Elias
    Kantarjian, Hagop
    Cortes, Jorge
    SEMINARS IN HEMATOLOGY, 2010, 47 (04) : 344 - 353
  • [10] Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia
    Breccia, Massimo
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2010, 34 (02) : 129 - 134
12345